LUYE PHARMA (02186): Nanjing Greenleaf receives a capital injection of 285 million yuan.

LUYE PHARMA (02186) announced that on January 26, 2026, Shenzhen Luye, Nanjing Xinye, Nanjing Xinan, Ningbo Xinda, and Nanjing Luye entered into a capital injection agreement. According to this agreement, Nanjing Xinan and Ningbo Xinda agreed to provide further capital to Nanjing Luye, totaling RMB 285 million. Following the completion of the capital injection, Shenzhen Luye, Nanjing Xinye, Nanjing Xinan, and Ningbo Xinda will hold 70.01%, 23.34%, 4.32%, and 2.33% respectively of Nanjing Luye. In terms of the capital injection by Nanjing Xinan and Ningbo Xinda into Nanjing Luye, the group has entered into a series of further transactions: according to the Nanjing Luye equity option agreement, Yantai Luye has the right to require each Xinda subscriber to sell their respective equity held in Nanjing Luye to Yantai Luye. According to the Nanjing Luye equity option agreement, each Xinda subscriber has the right to require Yantai Luye to repurchase their respective equity held in Nanjing Luye upon the occurrence of certain events. As of the date of this announcement, Nanjing Luye is held by Shenzhen Luye and Nanjing Xinye at 75% and 25% respectively. Nanjing Luye and its subsidiaries are mainly engaged in the production and sale of pharmaceuticals, focusing on the field of cancer treatment. Yantai Luye and Shenzhen Luye are wholly owned subsidiaries of the company, each mainly engaged in investment holding businesses.